First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center Preclinical animal…
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) — Porosome Therapeutics, Inc. (Porosome Therapeutics) today announced the development of novel first-in-class porosome-targeting small…
Quantum Transportation’s unique decoder is making another step forward by being validated in high-performance cloud environments Ra’anana, Israel, Feb. 24,…
In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC Real‑world evidence showed Pluvicto achieved…
A cost-optimized 5G RedCap module delivering high throughput, precise positioning, and scalable global connectivity for advanced IoT deployments SAN JOSE,…